Komori
Other Disclosures4218NICHIBAN CO.,LTD.Materials and Chemicals

Limited sales begin for “ブレスキャンTM,” a chest-applied wearable device that visualizes respiratory movement simply by being attached, offering a new option for pulmonary disease screening

NICHIBAN began limited sales of “Breath ScanTM,” an adhesive wearable device co-developed with サイントル株式会社, to medical institutions in April 2026. The company plans to gather needs from healthcare professionals through the limited sales program and begin full-scale production and sales in the second half of fiscal 2026.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Breath ScanTM adhesive wearable device
Applicable field (uses covered by this announcement)

Medical institutions, health checkups, and research on respiratory movement

Launch dateApril 2026 (limited sales began; actual)
What the company reported numerically
Usage history

Demonstration study involving approximately 300 people

Relationship between the counterparty and the company
NICHIBAN CO.,LTD.4218
Relationship with the Company

Joint development with サイントル株式会社. Clinical research was conducted at Shinshu University Hospital, and a demonstration study was conducted jointly with Rakuwakai Healthcare System.

Counterpartyサイントル株式会社, Shinshu University Hospital, and Rakuwakai Healthcare System

サイントル株式会社: Located in Bunkyo-ku, Tokyo; Representative Director: Ito Hideaki (伊藤秀明). Other details of Shinshu University Hospital and Rakuwakai Healthcare System: not disclosed

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Names of Products / Services CoveredBreath ScanTM adhesive wearable device
Counterpartyサイントル株式会社, Shinshu University Hospital, and Rakuwakai Healthcare System
Counterparty overviewサイントル株式会社: Located in Bunkyo-ku, Tokyo; Representative Director: Ito Hideaki (伊藤秀明). Other details of Shinshu University Hospital and Rakuwakai Healthcare System: not disclosed
Relationship with the CompanyJoint development with サイントル株式会社. Clinical research was conducted at Shinshu University Hospital, and a demonstration study was conducted jointly with Rakuwakai Healthcare System.
Launch dateApril 2026 (limited sales began; actual)
Applicable areaMedical institutions, health checkups, and research on respiratory movement
Usage historyDemonstration study involving approximately 300 people
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Practical utility was confirmed through clinical research and a demonstration study involving approximately 300 people, establishing the device as a tool for easily visualizing and monitoring respiratory status. The company will also use the limited sales program to gather a range of needs from healthcare professionals.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Limited sales begin for “ブレスキャンTM,” a chest-applied wearable device that visualizes respiratory movement simply by being attached, offering a new option for pulmonary disease screening | NICHIBAN CO.,LTD. (4218) timely disclosure | Komori